Columns

Healthcare Financing ◽

The following topics are under this section: Combination Immunotherapy for Hepatocellular Carcinoma Sustainability in Healthcare Financing MiRXES – A Game Changer in MicroRNA Applications

The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma

Journal of Hepatocellular Carcinoma ◽

10.2147/jhc.s301375 ◽

2021 ◽

Vol Volume 8 ◽

pp. 529-543

Author(s):

Zhimei Zhou ◽

Liteng Lin ◽

Yongcheng An ◽

Meixiao Zhan ◽

Ye Chen ◽

...

Keyword(s):

Tlr9 Agonist ◽

Intratumoural Injection

Laparoscopic liver resection for hepatocellular carcinoma in cirrhotic patients: a potential game changer toward global standardization of care

HepatoBiliary Surgery and Nutrition ◽

10.21037/hbsn.2017.04.02 ◽

2017 ◽

Vol ６ (３) ◽

pp. 203-204

Author(s):

Taizo Hibi ◽

Yuko Kitagawa

Keyword(s):

Liver Resection ◽

Laparoscopic Liver Resection ◽

Potential Game ◽

Global Standardization ◽

Cirrhotic Patients ◽

Combination immunotherapy with anti-VEGF/TKI for hepatocellular carcinoma: present and future perspective

HepatoBiliary Surgery and Nutrition ◽

10.21037/hbsn-20-707 ◽

2021 ◽

Vol 10 (2) ◽

pp. 241-245

Author(s):

Masatoshi Kudo

Keyword(s):

Future Perspective ◽

Anti Vegf

Atezolizumab and bevacizumab: the revolutionary duo as a game changer in advanced hepatocellular carcinoma

Immuno-Oncology Technology ◽

10.1016/j.iotech.2020.06.002 ◽

2020 ◽

Vol 7 ◽

pp. 1 ◽

Cited By ~ 1

Author(s):

D.X. Zhang

Keyword(s):

Advanced Hepatocellular Carcinoma ◽

Combination immunotherapy with OK-432, recombinant granulocyte-colony-stimulating factor and recombinant interleukin-2 for human hepatocellular carcinoma

Cancer Immunology Immunotherapy ◽

10.1007/s002620050262 ◽

1996 ◽

Vol 42 (2) ◽

pp. 127-131 ◽

Cited By ~ 8

Author(s):

T. Himoto ◽

Seishiro Watanabe ◽

Mikio Nishioka ◽

Takashi Maeba ◽

Satoshi Tanaka ◽

...

Keyword(s):

Interleukin 2 ◽

Human Hepatocellular Carcinoma ◽

Granulocyte Colony Stimulating Factor ◽

Colony Stimulating Factor ◽

Recombinant Interleukin 2 ◽

Stimulating Factor

Abstract 4286: TGF-β signature is a therapeutic biomarker for combination immunotherapy for hepatocellular carcinoma

10.1158/1538-7445.am2020-4286 ◽

2020 ◽

Author(s):

Jian Chen ◽

Xiaoping Su

Keyword(s):

Combination Immunotherapy

Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies

Liver Cancer ◽

10.1159/000503254 ◽

2019 ◽

Vol 8 (6) ◽

pp. 413-426 ◽

Cited By ~ 3

Author(s):

Masatoshi Kudo

Keyword(s):

Scientific Rationale

Nanobubbles Containing sPD-1 and Ce6 Mediate Combination Immunotherapy and Suppress Hepatocellular Carcinoma in Mice

International Journal of Nanomedicine ◽

10.2147/ijn.s305857 ◽

2021 ◽

Vol Volume 16 ◽

pp. 3241-3254

Author(s):

Yandi Tan ◽

Shiqi Yang ◽

Yao Ma ◽

Jinlin Li ◽

Qian Xie ◽

...

Keyword(s):

Combination Immunotherapy

Game Changer

Perspectives on Augmentative and Alternative Communication ◽

10.1044/aac20.1.17 ◽

2011 ◽

Vol 20 (1) ◽

pp. 17-18 ◽

Cited By ~ 5

Author(s):

Lateef McLeod

Keyword(s):

San Francisco ◽

Mobile Technology ◽

Technology Tools ◽

Communication Challenges ◽

Communication Needs ◽

Abstract Individuals with significant communication challenges need to communicate across many different venues. The author, from the perspective of an individual who uses AAC, discusses the strengths and weaknesses of both traditional AAC technologies and new mobile AAC technologies. He describes how access to AAC has allowed him to fulfill his dreams as a presenter and writer. He successfully manages a blog in San Francisco, writes grants, and has published his first book of poetry. Not one AAC device fits all of his communication needs; however, access to mobile technology tools has increased his flexibility across environments and given him another successful tool for communication.